Arena Still Awaiting DEA Classification

Arena Pharmaceuticals Inc. (Nasdaq: ARNA) narrowed first quarter losses to 9 cents per share from 18 cents per share in the year ago period but the company is still waiting for the Drug Enforcement Agency to classify its obesity treatment Belviq. Shares of the biopharmaceutical dropped 85 cents to $7.55.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here